Neurenati Therapeutics: Funding, Investors & Team (Sep 2026)
Neurenati Therapeutics is a biotechnology company that is working on a new treatment for Hirschsprung disease. They are leading the way in finding a unique solution for this serious gastrointestinal disorder, which is characterized by a lack of nerves in parts of the lower digestive system. Their advanced technology involves using growth factors to treat infants with Hirschsprung disease, with the goal of reducing the need for surgery and minimizing associated risks and complications.
Neurenati Therapeutics has raised $1.7M across 1 funding round on record, the most recent a Seed of $1.7M announced in Apr 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Neurenati Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2024.
Neurenati Therapeutics Funding Rounds
Neurenati Therapeutics Founders and Leadership Team
Contact details for the Neurenati Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Neurenati Therapeutics Funding Compared to Other Biotechnology Startups
Neurenati Therapeutics' latest round of $1.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Neurenati Therapeutics in Biotechnology and Montréal
Companies Similar to Neurenati Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Neurenati Therapeutics Funding FAQs
What does Neurenati Therapeutics do?
Neurenati Therapeutics is a biotechnology company that is working on a new treatment for Hirschsprung disease. They are leading the way in finding a unique solution for this serious gastrointestinal disorder, which is characterized by a lack of nerves in parts of the lower digestive system. Their advanced technology involves using growth factors to treat infants with Hirschsprung disease, with the goal of reducing the need for surgery and minimizing associated risks and complications.
How much funding has Neurenati Therapeutics raised?
Neurenati Therapeutics has raised $1.7M across 1 round on record. The most recent is a Seed of $1.7M announced in Apr 2024.
When did Neurenati Therapeutics last raise funding?
Neurenati Therapeutics' most recent funding round on record is a Seed of $1.7M, announced in Apr 2024.
Who founded Neurenati Therapeutics?
FundedIQ lists Rodolphe Soret (Founder) at Neurenati Therapeutics.
Where is Neurenati Therapeutics headquartered?
Neurenati Therapeutics is based in Montréal, Quebec, Canada.
How many employees does Neurenati Therapeutics have?
Neurenati Therapeutics is in the 1-10 employee band.
How does Neurenati Therapeutics' funding compare to other Biotechnology startups?
Neurenati Therapeutics' latest round of $1.7M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Neurenati Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Neurenati Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.